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A human liver cDNA library was screened by colony 
hybridization  with  two  mixtures of synthetic oligode- 
oxyribonucleotides as probes. These oligonucleotides 
encoded regions of @-factor XIIa as predicted  from  the 
amino acid sequence. Four positive clones were isolated 
that contained DNA coding for most of factor XI1 
mRNA. DNA sequence analysis of these  overlapping 
clones showed that they contained DNA coding for part 
of an amino-terminal extension, the complete amino 
acid sequence of plasma factor XII, a TGA stop codon, 
a 3' untranslated region of 150 nucleotides, and a 
poly(A)+ tail. The cDNA sequence predicts that plasma 
factor XI1 consists of 596 amino acid residues. Within 
the predicted amino acid sequence of factor XII, we 
have  identified three peptide bonds that  are cleaved by 
kallikrein  during  the  formation f &factor XIIa. Com- 
parison of the  structure of factor XI1 with  other pro- 
teins  revealed  extensive s quence identity  with  regions 
of tissue-type plasminogen activator (the epidermal 
growth  factor-like  region  and  the  kringle r gion) and 
fibronectin (type I and  type I1 homologies). As the type 
I1 region of fibronectin contains a collagen-binding 
site,  the homologous region in  factor XI1 may be re- 
sponsible for  the  binding of factor XI1 to collagen. The 
carboxyl-terminal  region of factor XI1 shares consid- 
erable amino acid sequence homology with  other  serine 
proteases including trypsin  and many clotting  factors. 
A preliminary  structural model of &factor XIIa is  pro- 
posed based on the  known high resolution x-ray dif- 
fraction  structures of trypsin, chymotrypsin, and elas- 
tase. 
Human blood coagulation factor XI1 (Hageman factor) is a 
glycoprotein that circulates in plasma as an inactive zymogen. 
The protein has been highly purified from human plasma 
(Revak et al., 1974; Griffin and Cochrane, 1976; Fujikawa and 
Davie, 1981) and consists of a single polypeptide chain of M, 
80,000. On activation, factor XI1 is converted to a serine 
protease that is capable of initiating the blood clotting cas- 
cade, the fibrinolytic system, and  the production of kinins 
(Kaplan, 1978; Ratnoff and  Saito, 1979; Heimark et al., 1980). 
*This work was supported in part by grants from the Medical 
Research Council of Canada (to R. T. A. M. and G. D. B.) and  the 
British Columbia Health Care Research Foundation (to R. T. A. M. 
and G.  D. B.) and by National Institutes of Health  Grant HL06350 
(to C.-J. S. E.). The costs of publication of this article were defrayed 
in part by the payment of page charges. This article  must therefore 
be hereby marked "advertisement" in accordance with 18 U.S.C. 
Section 1734 solely to indicate this fact. 
Deborah E. cool$, Cora-Jean S. Edgells, Gordon V. Louie$, Mark J. Zollery, Gary D. Brayer$, and 
Ross  T. A. MacGillivrayl 
From the $Department of Biochemistry,  University of British Columbia, Vancouver, British Columbia V6T 1 w5,  the 
$Department of p a t h o k m  University of North Carolina.  Chapel Hill, North Carolina 27514,  and the %'&ld Spring Harbor 
Factor XI1 readily binds to anionic surfaces such  as sili- 
cates, dextran sulfate, and sulfatides in vitro (Ratnoff and 
Rosenblum, 1958; Fujikawa et al., 1977,1980a). In uiuo, these 
binding properties may be responsible for the activation of 
factor XI1 when it comes in  contact with collagen or platelet 
membranes (Wilner et al., 1968; Harpel, 1972). Surface-bound 
factor XI1 has enzyme activity towards its  protein  substrates, 
prekallikrein and factor XI (McMillin et al., 1974; Saito, 1977; 
Heimark et al., 1980). These two proteins circulate in plasma 
as inactive zymogens complexed with high molecular weight 
kininogen (Thompson et al., 1977,  1979; van der Graaf et al., 
1982). Upon surface activation of the coagulation system, the 
high molecular weight kininogen-prekallikrein complex, the 
high molecular weight kininogen-factor XI complex, and fac- 
tor XI1 bind to anionic surfaces at  the site of injury (Wiggins 
et al., 1977; Thompson et al., 1979; Kerbiriou and Griffin, 
1979). Surface-bound factor XI1 activates prekallikrein by 
limited proteolysis. The resulting kallikrein cleaves factor XI1 
generating factor XIIa. The production of activated factor 
XI1 results  in  further reciprocal activation of prekallikrein 
and factor XII. Factor XIIa then activates surface-bound 
factor XI  and thence the rest of the clotting cascade. 
There  are multiple sites in factor XI1 that  are susceptible 
to cleavage by a number of proteases including kallikrein, 
plasmin, and trypsin (Margolis, 1958; Kaplan and Austen, 
1971; Meier et al., 1977; Dunn and Kaplan, 1982). Limited 
proteolysis by kallikrein activates surface-bound factor XI1 
and produces two active enzyme forms, a-factor  XIIa  and p- 
factor XIIa. A single cleavage of the zymogen generates a- 
factor XIIa while two more subsequent cleavages  by kallikrein 
yield @-factor XIIa (Revak et al., 1974; Dunn et al., 1982; 
Fujikawa and McMullen, 1983). Both active enzymes consist 
of two polypeptide chains held together by a disulfide bond 
(Revak et al., 1974, 1977). a-Factor  XIIa is comprised of two 
polypeptide chains of MI 52,000 and 28,000 while p-factor 
XIIa consists of two polypeptide chains of M, 2,000 and 
28,000. Amino-terminal sequence analysis has shown that  the 
M, 52,000 fragment in a-factor XIIa is derived from the 
amino-terminal region of factor XI1 (Fujikawa et al., 1980b) 
and contains the surface-binding site (Revak and Cochrane, 
1976; Revak et al., 1977). The M, 2,000 fragment of p-factor 
XIIa does not  bind to surfaces. Although the complete amino 
acid sequence of p-factor XIIa  has been determined (Fujikawa 
and McMullen, 1983), the origin of the MI 2,000 fragment  in 
the zymogen was not determined. However, the characteri- 
zation of a-factor  XIIa  has since been reported in an abstract 
by these authors (McMullen and Fujikawa, 1984). The M, 
28,000 fragments of both a- and @-factor XIIa  are identical 
and  contain the catalytic domain derived from the carboxyl- 
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terminal region of factor XI1 (Revak et aL, 1974, 1977). The 
catalytic domain of a- and @-factor XIIa shares extensive 
amino acid sequence homology  with other serine proteases, 
including  many blood clotting factors (see Jackson and Nem- 
erson, 1980; Fujikawa and McMullen, 1983). The sequence 
homology is highest at the activation regions and near the 
active sites of these proteases. 
In order  to characterize the zymogen form of factor XI1 
more thoroughly, we have isolated several cDNA clones coding 
for human factor XII. Together, these clones code for part of 
an amino-terminal extension (six amino acid residues), the 
complete  amino  acid sequence of plasma factor XII, a TGA 
stop codon, a 3’ untranslated sequence of 150 bp’ and a 
poly(A)+ tail. From the. cDNA sequence we predict that 
plasma factor XI1 consists of a single polypeptide chain of 
596 residues. Comparison of the predicted factor XI1 sequence 
with  the sequences of other proteins shows that factor XI1 
shares extensive amino acid identity with tissue-type plas- 
minogen  activator  (tPA) and fibronectin. Based on the known 
atomic coordinates of bovine trypsin (Marquart et al., 1983), 
porcine elastase (Sawyer et al., 1978), and bovine  chymotryp- 
sin  (Cohen et al., 1981), a three-dimensional model of @-factor 
XIIa has been constructed. The model predicts that: (i) there 
is a close structural relationship between the catalytic regions 
of these serine proteases and @-factor XIIa; (ii) the disulfide 
bonding  arrangement of the 14 cysteine residues in @-factor 
XIIa can be assigned; and (iii) the presence of an alanine 
residue rather than a serine residue at the a-carbon position 
190 may explain why some clotting factors cleave  preferen- 
tially at arginine residues rather than at lysine residues. 
MATERIALS AND METHODS 
Enzymes and Chemicals-Escherichia coli DNA polymerase I and 
Klenow fragment were purchased from Boehringer Mannheim, and 
deoxyribonuclease I was purchased from P-L Biochemicals. All other 
enzymes were purchased from Bethesda Research Laboratories or 
New England Biolabs. P-L Biochemicals also supplied deoxy- and 
dideoxyribonucleotide triphosphates, the M13 sequencing primer 
(heptadecanucleotide), and oligo(dT) cellulose (type 7). [LY-~’P] 
dNTPs (3000 Ci/mmol; 1 Ci = 3.7 X 10” Bq) and  [y3’P]ATP (3000 
Ci/mmol) were purchased from Amersham. Cellulose nitrate (BA-85) 
was purchased from Schleicher & Schuell. 
Synthesis of Oligodeozyribonucleotides-Two pools of mixed hep- 
tadecadeoxyribonucleotides were used as hybridization probes. Pool 
I (5’-dTCRAAYTGRTGNCCCCA-3’, where R represents both dG 
and d A ,  Y represents dT  and dC, and N represents dG, dA, dT,  and 
dC) was complementary to  the mRNA sequence coding for amino 
acid residues 133-138 of @-factor XIIa (Fujikawa and McMullen, 
1983). Pool I1 (5’-dCCYTGRCANGCYTCNGT-3’) was complemen- 
tary  to  the mRNA coding for residues 182-188  of @-factor XIIa.  Both 
pools of oligonucleotides were synthesized by using an Applied Bio- 
systems 380A DNA Synthesizer, and  the heptadecanucleotide frac- 
tions were purified by polyacrylamide gel electrophoresis in  the pres- 
ence of 8.3 M urea (Atkinson and  Smith, 1984). The oligonucleotide 
mixtures were labeled with [y-3ZP]ATP  and  T4 polynucleotide kinase 
(Chaconas and van de  Sande, 1980) to a specific activity of 1.1 X lo6 
cpm/pmol. Unincorporated [Y-~’P]ATP was removed by chromatog- 
raphy on a column of Sephadex G-25 (superfine) equilibrated and 
eluted with 5 mM Na2EDTA (pH 8.0), and  the excluded fraction was 
added directly to  the hybridization mixture. 
Screening a Human Liver cDNA  Library-An adult human liver 
cDNA library (Prochownik et al., 1983) was generously provided by 
S. H. Orkin (Children’s Hospital Medical Center, Boston). This 
library consists of double-stranded cDNA (>500 bp in length) cloned 
into  the  PstI  site of pKT218 by homopolymeric dGdC tailing. Ini- 
tially, 2 X lo5 colonies of the cDNA library were plated directly onto 
10 cellulose nitrate filters placed on  Luria broth,plates containing 
tetracycline (12.5  pg/mI). The colonies were grown and two sets of 
‘The abbreviations used are: bp, base pair(s); tPA, tissue-type 
plasminogen activator. 
replica filters were prepared (Hanahan  and Meselson, 1980; Fung et 
al., 1984). One set of the replica filters was hybridized with the 32P- 
labeled Pool I oligonucleotides and  the other set of filters was hybrid- 
ized to 32P-labeled Pool 11. Hybridization and washing conditions 
were as described by Fung et al. (1984). Colonies that hybridized to 
both pools of oligonucleotides were rescreened at lower  colony density. 
Plasmid DNA was prepared from positive colonies using the alkaline 
lysis method (Maniatis  et al., 1982). The cDNA library was subse- 
quently rescreened by colony hybridization (Hanahan  and Meselson, 
1980) using nick-translated factor XI1 cDNA restriction enzyme 
fragments as hybridization probes (Maniatis et al., 1975). All cloning 
experiments were performed in compliance with the Medical Re- 
search Council guidelines for recombinant DNA research. 
Restriction Endonuclease Mapping-Plasmid DNA was digested 
with one or more restriction endonucleases under conditions recom- 
mended by the manufacturers. The resulting fragments were analyzed 
by agarose or polyacrylamide gel electrophoresis. 
DNA Sequence Analysis-DNA sequence analysis was carried out 
essentially as described by Deininger (1983). Plasmid DNA was 
randomly sheared by sonication and  the resulting DNA fragments 
were fractionated on a 5% polyacrylamide gel. Fragments (300-500 
bp in size) were recovered by electroelution, and the ends were 
repaired with T4 DNA polymerase. The blunt-ended fragments were 
then ligated into  the SmaI site of M13mp8 and used to transform E. 
coli strain JM103 (Messing, 1983). Phage  containing cDNA sequences 
were identified by plaque hybridization (Benton and Davis, 1977) 
using nick-translated cDNA restriction  fragments as probes. Single- 
stranded DNA was isolated from positive plaques (Messing, 1983) 
and subjected to DNA sequence analysis using the chain  termination 
method (Sanger et al., 1977). This strategy resulted in  the determi- 
nation of most of the cDNA sequence. To complete the sequence 
analysis, three restriction enzyme fragments were subcloned into M13 
(see “Results”). All  DNA sequence data were analyzed by the DBU- 
TIL computer program of Staden (1982). 
Northern Blot Analysis-Poly(A)+ RNA was isolated from a sample 
of human liver by the guanidine hydrochloride method (Chirgwin et 
al., 1979). The poly(A)+ RNA (20 pg) was denatured with formalde- 
hyde/formamide, electrophoresed on a 1% agarose gel containing 
formaldehyde, and transferred to nitrocellulose as described by Man- 
iatis  et al. (1982). The blot was analyzed using nick-translated pc- 
HXII-501 (specific activity, 1.4 X 10’ cpm/pg) as a hybridization 
probe. Hybridization and washing conditions were as described for 
Southern  blots by Kan  and Dozy  (1978). 
Southern Blot Analysis-High molecular weight  DNA  was isolated 
from a liver sample of a female with no known hematological disorders 
using the method of Blin and Stafford (1976). DNA samples (10  pg) 
were digested with restriction endonucleases (40 units)  at 37 “C for 
18 h. The DNA fragments were separated by electrophoresis on a 1% 
agarose gel, denatured, and transferred to nitrocellulose as described 
by Southern (1975). The blot was analyzed using pcHXII-501, pre- 
viously labeled by nick translation (specific activity, 9 X 10’’ cpm/pg) 
as a hybridization probe. Hybridization and washing conditions were 
as described for the Northern  blot analysis. 
Sequence Alignment and  Structural Modelling-The amino acid 
sequence alignment of @-factor XIIa  to  the pancreatic serine proteases 
trypsin, chymotrypsin, and elastase was based on considerations of 
both sequence homology and topological equivalence (James et al., 
1978). During this procedure the preservation of regions of identical 
amino acid sequences near the catalytic residues and  the homologous 
positioning of disulfide bridges were  given the highest priority. Inser- 
tions were introduced only when such residues were absent  in the 
amino acid sequences of all three pancreatic enzymes and placed only 
where inspection of the known tertiary structures of the pancreatic 
enzymes indicated that sufficient room  was available to accommodate 
them. 
The modelling procedure used to predict the  tertiary structure of 
&factor XIIa was based primarily upon the known high resolution 
structure of bovine pancreatic trypsin (Marquart  et al., 1983). An 
initial model was constructed with coordinates from the polypeptide 
chain backbone of trypsin and those amino acid side chains conserved 
in the primary  structures of both  proteins (84 residues). Changes in 
the identity of nonhomologous amino acids (139 residues) were ac- 
complished in  the following manner. The original trypsin side chain 
was replaced by the appropriate @factor XIIa side chain (as obtained 
from a standard amino acid group dictionary (Sielecki et al., 1979)) 
utilizing a least  squares  fitting procedure. In  this process, the maximal 
number of conformational torsional angles from the original trypsin 
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side chain were conserved in the positioning of the new @-factor XIIa 
side chain. 
With  the exception of residue 245 at  the carboxyl terminus, there 
are no deletions in the amino acid sequence of @-factor XIIa with 
respect to trypsin  (Table  I).  Insertions in  the @-factor XIIa sequence 
were handled in one of two ways. The  first method was based on the 
strong  tertiary  structural homology known to exist among the  pan- 
creatic  serine proteases, chymotrypsin, elastase, and trypsin (Bode et 
al., 1976; James et al., 1978; Sawyer et al., 1978; Cohen et al., 1981). 
When @-factor XIIa  insertions  (with respect to  the trypsin sequence) 
were also present  in the sequences of chymotrypsin or elastase, the 
portion of polypeptide chain from the appropriate protein was used 
as a guide in the placement of the comparable insertion  in the @- 
factor XIIa model.  Amino acid positions modelled in this way included 
residues 67-68, 126, 131, 170A, 172, 203-205, and 206. Amino acid 
insertions unique to @-factor XIIa (residues 61 A-C, 109 A-E, and 
205  A-C) occurred at  the ends of existing @-loops in the structures of 
the pancreatic enzymes and were handled by a second method. The 
inserted residues were  modelled as extended @-loops and merged to 
the polypeptide chain backbone at  the appropriate positions. All three 
TABLE I
Amino acid  sequence alignment of the catalytic regions of human @-factor XIIa (FXII), bovine trypsin (TRYP), 
porcine elastase (ELAS), bovine chymotrypsin (CHYM), and human tissue-type plasminogen activator (tPA) 
The sequences of trypsin, elastase, chymotrypsin, and  tPA  are  taken from Marquart et al. (1983), Sawyer et al. 
(1978), Cohen et al. (1981), Pennica et al. (1983), respectively. The numbering system used is based on that of 
chymotrypsinogen A (Hartley and Kauffman, 1966), with insertions in  the sequences of related enzymes denoted 
by letters (36A, 36B, etc.). Deletions are indicated by dashed lines. Identical residues in corresponding positions of 
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insertions occur at  the surface of the enzyme where there is sufficient 
room for their placement. No disruption of nearby segments of 
conserved polypeptide chain structure was required during this fitting 
process. 
In order to obtain the best overall structural model, the full set of 
initial  atomic  coordinates for &factor XIIa were further subjected to 
10 cycles of structural idealization (final root mean square 6 for bond 
distances, 0.006 A, Konnert  and Hendrickson, 1980). It is this final 
predicted model that is discussed herein. 
RESULTS 
Isolation of Factor XZZ cDNA Clones-Two hundred  thou- 
sand  bacterial colonies of a human liver cDNA library were 
screened with two mixtures of synthetic oligonucleotides that 
encoded two regions of  ,&factor XIIa  as predicted from the 
known amino acid sequence. Although each of the oligonucle- 
otide  mixtures hybridized to about 60 different colonies, only 
two colonies hybridized to both. After rescreening at lower 
colony density, plasmid DNA was isolated from the two 
positives that were designated pcHXII-11 and pcHXII-14 
(Fig. 1). Subsequent sequence analysis revealed that these 
plasmids contained DNA coding for the known amino acid 
sequence of p-factor XIIa. Because pcHXII-11 and pcHXII- 
14  contained only short cDNA inserts, 2 x lo5 colonies of the 
cDNA library were rescreened with the 32P-labeled PstI  insert 
of pcHXII-11 as a hybridization probe. Thirty-six positive 
clones of various lengths were obtained; plasmids pcHXII-17 
and pcHXII-501  contained the longest cDNA inserts  and were 
studied  further.  Restriction endonuclease mapping of the four 
positive plasmids showed that they contained overlapping 
DNA (Fig. 1) except that pcHXII-17  appeared to contain a 
deletion (Fig. 1, open dashed bar). This was confirmed by 
subsequent DNA sequence analysis (see next  section). 
Sequence Analysis of Human Factor XZZ cDNA Clones- 
The strategy used to determine the nucleotide sequence of the 
four clones, pHXII-11, -14, -17, and -501 is shown in Fig. 1. 
The thick arrows represent the sequence determined from 
M13 phage containing randomly sheared DNA. Although 
*e+ 
more than 90% of the nucleotide sequence was determined 
using this strategy, few random clones were isolated that 
overlapped the AuaI site of factor XI1 cDNA (Fig. 1). To 
complete the nucleotide sequence analysis, plasmid pcHXII- 
501 (Fig. 1) was digested with PstI and  the 1200- and 280-bp 
fragments were isolated by polyacrylamide gel electrophoresis. 
The 280-bp fragment was cloned directly into  the  PstI site of 
M13mp8. The 1200-bp fragment was digested with both AuaI 
and  SmaI,  and  the ends were made blunt-ended using the 
Klenow fragment of E. coli DNA polymerase I (Smith et al., 
1979). The resulting PstIIAuaI and AuaIISmaI fragments 
were isolated by polyacrylamide gel electrophoresis and sub- 
sequently ligated into  the  SmaI site of M13mp18. The DNA 
sequence analysis of these clones is shown in Fig. 1 (thin 
arrows). 
The nucleotide sequences of the four factor XI1 cDNA 
clones were compiled into a consensus sequence (Fig.  2). Each 
nucleotide in  the sequence was determined an average of 6.6 
times, and 84% of the sequence was determined on both 
strands. In  the regions of overlap, the four factor XI1  cDNA 
clones contained identical nucleotide sequences, with one 
exception. In agreement with the restriction map of pcHXII- 
17 (Fig. l),  the DNA sequence analysis showed that this 
plasmid contains a deletion of 53 bp between nucleotides 1330 
and 1383 (Fig. 2). The deleted region is flanked by an inverted 
repeat having the sequence: CTCGC CGTC (nucleotides 
1320-1329 and nucleotides 1383-1392,  Fig. 2). This deletion 
alters  the reading frame of factor XI1 mRNA and probably 
represents a cloning artifact. 
Predicted Amino Acid Sequence of Human Factor XZZ- 
Translation of the cDNA sequence using the  standard genetic 
code results  in a single open reading frame coding for human 
factor XI1 (Fig.  2). The derived amino acid sequence is iden- 
tical to those regions of human factor XI1 that have been 
determined by protein  chemistry techniques. Nucleotides 19- 
78 encode the amino-terminal region of factor XI1 (Fujikawa 
G 
*e* *e+ *.+ *e+ 
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FIG. 1. Restriction map and sequencing strategy for human factor XI1 cDNA. The bars below the 
restriction  map  represent cDNA clones pcHXII-11, pcHXII-14, pcHXII-17, and pcHXII-501 and include regions 
coding for the signal peptide (dotted bar), the heavy chain of a-factor XIIa (open  bar), the light and heavy chains 
of &factor XIIa (solid bars), and  the 3' untranslated region (hatched bar). The open dashed line in pcHXII-17 
represents a deletion (see text for details). Arrows below the cDNA clones represent the sequencing strategy used, 
where each arrow represents an M13 clone. The  extent of sequencing is indicated by the length of the arrows. DNA 
sequence determined on  the coding strand is shown by an arrow pointing left; sequence determined  on the noncoding 
strand is shown by an arrow pointing right. Thick arrows represent DNA sequences obtained from randomly 
sheared cDNA fragments and thin arrows represent sequences obtained from restriction enzyme fragments. The 
scale at  the bottom represents nucleotides in kilobase pairs (kb). 
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FIG. 2. Nucleotide sequence of human factor XI1 cDNA. The sequence was determined by analysis of the 
overlapping clones shown in Fig. 1. The predicted amino acid sequence of human factor XI1 is shown above the 
DNA sequence. The oligonucleotide sequences used for screening the cDNA library are represented by boxes at 
nucleotides 1474-1490 and 1627-1643. The putative signal peptide is numbered backwards from the putative signal 
peptidase cleavage site (open arrow). The proteolytic cleavage sites that give rise to p-factor XIIa  are shown by the 
heauy arrows (at amino acid residues 334,  343, and 353). The residues that make up the catalytic triad (His-393, 
Asp-442, and Ser-544) are underlined. The TGA stop codon is located at nucleotides 1807-1809 and followed by 
the 3' untranslated region (nucleotides 1810-1959) and a poly(A)+ tail. The poly(A)+ recognition site AATAAA is 
encoded by nucleotides 1937-1942. A carbohydrate attachment  site (Fujikawa and McMullen, 1983) is indicated 
by the solid diamond. 
et al., 1980b; Fujikawa and Davie, 1981). Since the amino- 
terminal residue of plasma factor XI1 is encoded by nucleo- 
tides 19-21 (Fig. 2), the factor XI1 cDNA sequence also 
encodes part of an amino-terminal extension (nucleotides 1- 
18, Fig. 2). Nucleotides 1021-1047 and 1078-1806 encode the 
light and heavy chains of p-factor XIIa as determined by 
Fujikawa and McMullen (1983). In  the presence of an anionic 
surface, kallikrein cleaves factor XI1 at a position carboxyl- 
terminal to Arg-353, resulting in  the formation of a-factor 
XIIa (Fujikawa and McMullen, 1983). Further proteolytic 
cleavages occur carboxyl-terminal to Arg-334 and Arg-343 
and give rise to @-factor XIIa. During the formation of @- 
factor XIIa, residues 1-334 and 345-353 of factor XI1 are 
removed. The codon for the carboxyl-terminal residue of the 
heavy chain of p-factor XIIa (Ser-596) is followed  by a TGA 
stop codon (nucleotides 1807-1809,  Fig. 2), a 3' untranslated 
region of 150 nucleotides and a poly(A)+ tail. Nucleotides 
1937-1942 contain the sequence AATAAA that  is involved in 
the polyadenylation of mRNA (Proudfoot and Brownlee, 
1976; Wickens and  Stephenson, 1984). This sequence occurs 
17 nucleotides upstream of the poly(A)+ tail. 
The predicted amino acid sequence of factor XI1 corre- 
Human Factor XII  cDNA 13671 
sponds to a mature protein of 596 amino acids. The amino 
acid composition of plasma factor XI1  was determined to be 
as follows: Alasl, Arg39, Asn13, Asp22, 1/2-Cys40, Gln37, GlU31, 
Gly4s,  His27,  Ileg, Lew,  Lys19,  Met4,  Phe15,  pro.056, S e s ~ ,  Thr34, 
Trp,,, Tyr19, and Vab. From the predicted amino acid se- 
quence, the molecular  weight of plasma factor XI1 is 66,915 
in  the absence of carbohydrate and 80,427 with the addition 
of 16.8% carbohydrate (Fujikawa and Davie, 1981). Within 
experimental error, both the predicted amino acid  composi- 
tion and molecular weight of factor XI1 are in excellent 
agreement with those determined for the purified protein 
(Griffin and Cochrane, 1976;  Fujikawa and Davie,  1981). 
A 2.40-kb mRNA from Liver Codes for Human Factor XII- 
To determine the size of factor XI1 mRNA, human liver 
poly(A)+ RNA  was electrophoresed on  an agarose gel under 
denaturing conditions and  transferred to nitrocellulose. The 
blot was hybridized to 32P-labeled pcHXII-501, which con- 
tains 1959  bp of coding  sequence. Autoradiography revealed 
a single band that was  2,400 f 100 nucleotides in size  (Fig. 
3A). Since eukaryotic mRNAs  usually contain poly(A)+ tails 
of 180-200 nucleotides (Perry, 1976), we conclude that our 
longest clone is probably missing about 250 nucleotides of the 
mRNA  sequence. 
The Human Factor XZZ Gene-As an initial  step towards 
the characterization of the human factor XI1  gene, Southern 
blots of human liver  DNA  digested with several restriction 
endonucleases were  hybridized to 32P-labeled factor XI1  cDNA 
(pcHXII-501). Autoradiography revealed several hybridizing 
bands in each of the restriction enzyme digests (Fig. 3B). This 
suggests that the human genome contains either a single 
factor XI1  gene containing several introns or contains multi- 













FIG. 3. Analysis of the mRNA and the gene coding  for  factor 
XII. A ,  human liver poly(A)+ RNA was electrophoresed in a dena- 
turing agarose-formaldehyde gel and was transferred to nitrocellulose. 
The filter was hybridized with 32P-labeled pcXII-501. The filter was 
exposed for 18 h at -70°C with Lightning Plus intensifying screens 
(DuPont). The positions of RNA size standards  are indicated, includ- 
ing mammalian 28 S (4.72 kb) and 18 S (1.87 kb) rRNA and E. coli 
23 S (2.90 kb) and 16 S (1.54 kb) rRNA (Noller, 1984). B, human 
liver DNA was digested by various restriction enzymes and electro- 
phoresed in a 1.0% agarose gel. After denaturation, the DNA was 
transferred to nitrocellulose and hybridized with 32P-labeled pcHXII- 
501. The filter was autoradiographed for 4 days at  -70 "C with 
intensifying screens. Lane M shows the positions of "P-labeled X- 
HindIII DNA used as molecular weight markers. The human DNA 
was digested with EcoRI (lane I), HindIII (lane 2), PstI (lane 3), and 
BamHI (lane 4). 
DISCUSSION 
Factor XII  cDNA  Clones-A factor XI1 cDNA  of  1959 bp 
was isolated from a cDNA library prepared from human liver 
mRNA. This cDNA (pcHXII-501) codes  for part of a leader 
peptide followed  by the  entire coding  region of plasma factor 
XII, a TGA stop codon, a 150-bp noncoding  region at  the 3' 
end, and a poly(A)+ tail of at least 75 bp. 
The cDNA sequence data have enabled us to locate the 
kallikrein cleavage sites (solid arrows, Fig. 2) that produce p- 
factor XIIa during zymogen activation (Cochrane et al.,  1973; 
Revak et al.,  1977; Dunn et al., 1982). The  three cleavage sites 
occur carboxyl-terminal to arginine residues in  the sequences: 
Leu-Thr-Arg, Gly-Gln-Arg, and Met-Thr-Arg. Because kalli- 
krein does not recognize a unique sequence, however, the 
locations of other kallikrein cleavage sites in the M, 52,000 
fragment of a-factor XIIa cannot be determined from the 
cDNA  sequence data. 
Factor XI1 is a secreted protein and would  be  expected to 
contain a signal peptide which functions in  the  transport of 
the protein across the rough endoplasmic reticulum mem- 
brane (Blobel et al.,  1979). The cDNA sequence predicts that 
factor XI1 is synthesized as a precursor containing an amino- 
terminal extension of at least six amino acid  residues  (encoded 
by nucleotides 1-18, Fig. 2). Cleavage of a Ser-Ile bond (en- 
coded by nucleotides 16-21, Fig. 2) in the precursor would 
give rise to plasma factor XII. This bond cleavage is consistent 
with the specificity of signal peptidase (Watson, 1984);  from 
the present study, however, it is unclear whether nucleotides 
1-18 encode part of a signal peptide or another type of 
precursor sequence. 
Homologies  with Other Proteins-Comparison of residues 
1-276 of factor XI1 with protein sequences in  the National 
Biomedical Research Foundation (Washington, D.  C.) Protein 
Data Base reveals extensive sequence homology with both 
fibronectin and tPA. Based on these sequence  homologies, a 
schematic representation of the structure of factor XI1 is 
shown in Fig. 4. This structure is based on five different 
regions that share homology with regions of either fibronectin 
or tPA. In addition, factor XI1 contains a proline-rich region 
that does not share sequence homology with any known 
protein sequence. Each of these six  regions of factor XI1 are 
discussed in detail in  the following  sections. 
The amino-terminal region of factor XI1  (region  A-B, Fig. 
4) shares sequence homology with the type I1 homology re- 
gions of fibronectin. The type I1  homologies are each  com- 
posed of about 60 residues including four half-cysteine resi- 
dues (Petersen et al., 1983) and share approximately 54% 
sequence homology with each other (31/57  residues in corre- 
sponding positions are identical). Residues 13-69 of factor 
XI1 share 39%  sequence homology (22/57  residues are iden- 
tical) and 40%  sequence homology (23/57  residues are iden- 
tical) with the two fibronectin sequences,  respectively,  includ- 
ing the four half-cysteine residues (Fig. 5A). The type I1 
homologies probably comprise the collagen-binding site in 
fibronectin (see Yamada, 1983); by analogy, the region of 
factor XI1 that shares sequence homology to the type I1 
regions  may  be  responsible  for the collagen-binding properties 
of factor XII. 
Two  regions of factor XI1 (regions B-C and D-E, Fig. 4) are 
homologous to an epidermal growth. factor-like sequence that 
has been found in many proteins including the 19-kDa protein 
from  Vaccina virus, transforming growth factor type 1, tPA, 
and several clotting factors (Blomquist et al., 1984; Doolittle 
et al., 1984). In each of these proteins, there is a highly 
conserved  region of  50 amino acids  with nine invariant cys- 
teine  and glycine  residues.  After the insertion of three gaps 
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FIG. 4. Proposed  model  for human factor XII. The model was 
based on  amino acid sequence homologies with human tPA (Pennica 
et al., 1983;  Ny et al., 1984) and bovine fibronectin (Petersen et al., 
1983). Thin arrows demarcate the proposed protein structural do- 
mains found in human  factor  XII. Region A-B represents  a fibronec- 
tin type I1 homology; B-C and D-E are growth factor-like regions; C- 
D region is  a fibronectin type  I homology; region E-F is  a kringle 
structure; F-G is a proline-rich region whose structure is undefined, 
and G-COOH represents the catalytic region (see text for details). 
Disulfide bonds have been inserted according to  their arrangement 
in  the homologous domains of other proteins; however, the disulfide 
bond arrangement of the fibronectin type I1 region has not been 
determined. The disulfide bonds in  the catalytic region were based 
on the proposed model of @-factor XIIa (see “Discussion”). Kallikrein 
cleavage sites that give rise to @-factor XIIa are indicated by the 
heavy arrows. 
in  the factor XI1 sequences, all cysteine residues align per- 
fectly (Fig. 5B). The carboxyl-terminal growth factor domain 
also contains the invariant glycine residues; in  the amino- 
terminal domain, however, one invariant glycine residue has 
been replaced with a histidine. 
Separating the two growth factor-like regions of factor XI1 
is a 43-amino acid peptide (regions C-D, Fig. 4) that shares 
limited sequence homology with the type I regions of fibro- 
nectin (Fig. 5C). Fibronectin contains at least nine type I 
regions each of which are characterized by two disulfide bonds 
giving a two-loop structure that has been named a “finger” 
domain (Petersen et al., 1983). The function of the finger 
domains  in  fibronectin  is unclear but  they may be involved in 
fibrin-binding (see Yamada, 1983). 
Another  type of homology found in factor  XI1  is the kringle 
domain (region E-F, Fig. 4). Kringle domains are typically 80 
amino acids in length and form three  characteristic disulfide 
bonds. Kringles have been found in  prothrombin (Magnusson 
et al., 1975), plasminogen (Sottrup-Jensen et al., 1978), tPA 
(Pennica et al., 1983), and urokinase (Giinzler et al., 1982) 
and  share approximately 40% homology with each other  in- 
cluding six invariant half-cystine residues (see Jackson and 
Nemerson, 1980). An alignment of one of the kringle regions 
of tPA with factor XI1  is shown in Fig. 5 0 .  If three gaps are 
inserted  into the factor XI1 sequence, the kringles share 41% 
sequence homology (36 out of 87 residues are identical). The 
function of the kringle regions is unclear but they may be 
involved in  the binding of factor XI1 to fibrinogen and fibrin 
(Sottrup-Jensen et al., 1978; Lucas et al., 1983). The presence 
of both a finger domain and a kringle suggests that  the fibrin 
binding capacity of factor  XI1 may be important in uiuo. One 
consequence of fibrin binding is that on initiation of the 
clotting cascade, factor  XI1 would  be trapped  in the growing 
network of fibrin. Consequently, factor XI1 (or a-factor  XIIa) 
would be available for the subsequent initiation of the fibrin- 
olytic cascade. 
The kringle structure is followed  by a region (residues 279- 
330,  Fig. 2; region F-G, Fig. 4) in which 33% of the residues 
are proline (17 out of 52). Despite the high proline content, 
this region does not  share  any sequence homology with other 
proline-rich proteins  such  as  those from salivary glands (Zie- 
mer et al., 1984).  However, residues 299-308  of the proline- 
rich region of factor XI1 share sequence homology with resi- 
dues 29-38 of calf thymus high-mobility group protein 17 
(Walker et al., 1977) in which 8 out of 10 residues in corre- 
sponding positions are identical. The significance of this 
homology and  the function of the proline-rich region of factor 
XI1 are unclear. 
Downstream of the proline-rich region in factor XI1 is the 
catalytic region (region G to  the COOH terminus, Fig.  4) that 
shares amino acid sequence homology with other  serine  pro- 
teases. An alignment of the amino acid sequences of the 
catalytic regions of p-factor XIIa,  tPA,  and the  three  pan- 
creatic serine proteases is given in  Table I.  An analysis of the 
sequence homology between these enzymes is summarized in 
Table 11. It is notable that  the sequence homology between 8- 
factor XIIa and the pancreatic enzymes (average value of 
35%) is comparable to the homology present between the 
pancreatic enzymes themselves (average value of 42%). The 
strong  structural homology between @-factor XIIa  and  the 
pancreatic proteases has allowed us to develop a structural 
model of  /3-factor XIIa based on the known three-dimensional 
structures of the pancreatic enzymes (see next section). 
From these sequence comparisons, it can be seen that factor 
XI1 shares remarkable sequence homology with tPA (Ny et 
al., 1984), a protease that converts plasminogen to plasmin in 
the fibrinolytic pathway (see Collen, 1980). The complete 
amino acid sequence of human tPA  has been predicted from 
the cDNA sequence (Pennica et al., 1983) and shows that tPA 
consists of a finger domain, a growth factor-like domain, two 
kringle structures,  and the catalytic domain. This organiza- 
tion  is similar to regions C to  the COOH terminus of factor 
XI1 except that one of the tPA kringles is replaced by the 
proline-rich region (Fig.  4). 
It has been suggested that the genes coding for multi- 
domainal proteins may have evolved by joining of exons 
coding for separate  functional regions (Gilbert, 1979). In  the 
case of factor XII, at least seven potential domains can be 
identified (Fig.  4).  We are now characterizing the positions of 
the  introns  in  the factor XI1 gene, which will  allow a compar- 
ison of this gene to  the  tPA  (Ny et al., 1984) and fibronectin 
(Hirano et al., 1983) genes. This analysis should shed light on 
the evolution of the factor XI1 gene. 
A Model of the Tertiary Structure of &Factor XIIa-Thus 
far, it  has  not been possible to determine the tertiary  structure 
of any of the clotting proteases using x-ray diffraction tech- 
niques. The major difficulties encountered in  the  structural 
determination of these enzymes have been either an inability 
to isolate sufficient material  or to prepare suitable crystalline 
forms. The absence of direct structural  studies was the pri- 
mary incentive in  the development of the present  structural 
model for @-factor XIIa. Although this model should only be 
considered a preliminary approximation of the structure of p- 
factor  XIIa, it does provide a vehicle for gaining additional 
insight into  the function of this enzyme. 
The level of sequence homology observed between the  pan- 
creatic proteases (41%) has subsequently been shown to trans- 
late  into a substantially higher degree of tertiary  structure 
homology (-85%, James et al., 1978). Since the level of 
sequence homology between these enzymes and p-factor XIIa 
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FIG. 5. Homologies between the amino acid sequences of human factor XII, bovine fibronectin 
(Petersen et ul., 1983), and  human tissue-type plasminogen  activator  (Pennica et ul., 1983). Identical 
residues in corresponding positions are bow& gaps have been inserted in the sequences to maximize  homology. A,  
comparison of segment S3, residues 14-73 (type  11-l), and residues 74-130 (type 11-2) of fibronectin with residues 
13-69 of factor XI1 (FXII). B, comparison of residues 51-84 of tissue-type plasminogen activator (tPA) and 
residues 79-111 (FXII-I) and residues 159-190 (FXZZ-2) of factor XII. Arrows denote glycine and cysteine residues 
that  are invariant in this type of  homology (see text for details). C, comparison of segment S1, residues 17-57 (type 
I-I)  and segment S1 residues 66-104 ( t y p e  I-2) of fibronectin with residues 116-151 of factor XI1 (FXII). D, 
comparison of residues 87-173 of tissue-type plasminogen activator ( P A )  with residues 193-276 of factor XI1 
(FXII). 
TABLE I1 
Comparative analysis of the amino acid  sequence alignment between 
the catalytic regions of @-factor XZIa and the pancreatic serine 
proteases 
The  total number of residues in each protein  is given in parentheses 
below its name in  the heading. For each pair of proteins aligned in 
Table I, the matrix  contains the number of identical residues followed 
by the overall sequence homology (given as a percentage of the smaller 





8-Factor XIIa 86 (35%) 79 (33%) 84 (38%) 
Chymotrypsin 94 (41%) 101 (45%) 
Elastase 87 (39%) 
is similar (-36%), one might also anticipate a corresponding 
level of tertiary  structure homology between @-factor XIIa 
and  the pancreatic serine proteases. The modelled structure 
of @-factor XIIa and  the structure of trypsin, determined by 
x-ray diffraction techniques, are shown in Fig. 6. Beyond 
indicating tertiary  structure homology, our current model of 
&factor XIIa provides a basis for understanding the impli- 
cations of amino acid sequence  differences  between this  en- 
zyme and its pancreatic counterparts. For example, it is 
known that all 14 cysteine residues of @-factor XIIa are 
involved in disulfide  bridging (Fujikawa and McMullen,  1983). 
From the sequence alignment of @-factor XIIa (Table I),  it is 
apparent that four  disulfide  bridges  (involving  residues 42- 
58,136-201,168-182, and 191-220) are conserved in all three 
pancreatic enzymes, and a further homologous  disulfide  bridge 
is shared with chymotrypsin (residues 1-122). The disulfide 
bridging pattern of the remaining four cysteine residues of @- 
factor XIIa cannot be determined from primary structure 
alignments alone. However, a tentative placement of these 
disulfide  bridges can be  made as shown  in Fig.  6, Within the 
tertiary  structure model of @-factor XIIa, pairing of the re- 
maining cysteines is clearly evident, since Cys-50  lies nearby 
Cys-111, and Cys-77 is near Cys-80. Indeed, in both cases 
suitable disulfide bonds can be  made without disturbing the 
surrounding polypeptide chain structure  and were incorpo- 
rated  into  the final @-factor XIIa structure (see  Fig. 6). 
Also evident in Fig. 6 are the positions of major insertions 
that occur in  the amino acid  sequence of  /3-factor XIIa (resi- 
dues 61 A-C, 109 A-E, and 205  A-C).  All three of these occur 
towards the end of existing surface  @-loops in  the pancreatic 
enzymes  (see Fig. 6B);  two insertions are positioned on the 
forward active site face of the enzyme (residues 61 A-C and 
109  A-E), and  the  other is positioned towards the back surface 
of the enzyme (residues 205 A-C). Thus,  the insertions ob- 
served  for  /3-factor XIIa occur at sites easily  accommodated 
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FIG. 6. Stereo-drawings  of  the a- 
carbon  backbones  of (A)  the  modeled 
structure of human &factor XIIa 
and (B)  the  three-dimensional  struc- 
ture  of  bovine  pancreatic  trypsin as
determined  by x-ray diffraction 
techniques  (Marquart et  al., 1983). 
Similar views  of both enzymes are pre- 
sented, with the active site region of each 
located towards the center of these draw- 
ings. Amino acid sequence comparisons 
show that 84 amino acids (-38%) are 
conserved between @-factor XIIa and 
trypsin (see Tables  I and 11). Of these, 
the largest portions  are found around the 
active site residues His-57, Asp-102, Ser- 
195, and Ser-214. Open  virtual  bonds rep- 
resent the positions of the six disulfide 
bridges present  in  trypsin and  the seven 
proposed for @-factor XIIa. 
FIG. 7. Stereo-drawings  of  the ac- 
tive site regions  of human &factor 
XIIa (panel A)  and bovine pan- 
creatic  trypsin (panel B).  The p-fac- 
tor  XIIa  structure was modeled on the 
known tertiary structure of trypsin (see 
text for details). In both cases the poly- 
peptide chain backbone is drawn with 
solid black bonds and side chains with 
open  virtual bonds. The direction of  view 
presented in both drawings is the same 
as that in Fig. 6. For illustrative pur- 
poses, the four amino acids of the bovine 
pancreatic  trypsin  inhibitor  (Pro-13, 
Cys-14, Lys-15, and Ala-16) bound di- 
rectly in the active site of trypsin are 
also drawn. The inhibitor polypeptide 
chain backbone is drawn with wide solid 
black bonds and  the side chains  are 
drawn as wide  striped  virtual  open bonds. 
For clarity, inhibitor amino acids have 
been labeled (P3 through PI ') according 
to  the surface binding subsite (Schechter 
and Berger, 1967) that each was found 
to occupy (Marquart et al., 1983). For 
the purpose of comparison, the same in- 
hibitor residues have also been posi- 
tioned and drawn in  the modeled active 
site of p-factor XIIa. 
" 
A 
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within the overall structural framework of the pancreatic 
enzymes. Note that,  in  the present study, the five additional 
N-terminal  amino acids of @-factor XIIa have not been in- 
cluded in our  structural model. These residues have no coun- 
terparts  in  the pancreatic enzymes and therefore  their place- 
ment could not be accomplished with an acceptable degree of 
confidence. However, these additional residues are unlikely 
to influence the catalytic activity of /3-factor XIIa, being 
positioned on  the extreme  rear surface of the enzyme in  the 
orientation given in Fig. 6 (see the placement of residue 1). 
The overall pattern of variable and constant regions of 
sequence homology observed between other blood coagulation 
and pancreatic proteases is also preserved in comparisons 
with @-factor XIIa.  Thus, the present work, in agreement with 
other modelling studies  (Furie et al., 1982), suggests that  the 
basic core structural framework of the blood coagulation 
proteins  is very similar to  that of the pancreatic  serine  pro- 
teases. However, the exterior molecular surfaces of the coag- 
ulation proteins, which are composed in large part of six 
variable regions of sequence, are unique and are probably 
related to  the individual physiological function of each en- 
zyme. The insertion of 5 residues at residue 109 in  constant 
region CR3 of @-factor XIIa  is  the one notable exception to 
the overall pattern of constant  and variable sequence regions 
proposed by Furie et al., 1982. The sequence alignment of this 
insertion in &factor XIIa  cannot be accommodated elsewhere 
since it is fixed on  either side by the placement of Asp-102 
and Cys-122 (involved in a disulfide bridge with Cys-1), a 
feature conserved in  the  structure of chymotrypsin. Although 
absent  in  thrombin,  factor  Xa and factor IXa, this insertion 
is also present  in tPA (see Table I) and therefore  appears to 
be more than  just a unique structural  feature of @-factor XIIa. 
Thus, we propose that a further variable region be defined to 
describe insertions occurring at residue 109. 
In common with  other variable regions of amino acid se- 
quence, the 5-residue insertion at position 109 occurs on  the 
surface of the enzyme and  is most probably related to  the 
ability of @-factor XIIa to recognize the physiological molec- 
ular surfaces with which it must  interact. It is  notable that 
the carbohydrate moiety of @-factor XIIa  (bound to Asn-74; 
Fujikawa and McMullen, 1983) is positioned near  this inser- 
tion  and also on  the  substrate binding face of the enzyme (see 
Fig.  6A). Specialized surface features  such as these and  the 
variable regions of sequence already discussed provide a mech- 
anism by which complex cascade pathways like those involved 
in blood coagulation can occur by the specific recognition of 
substrate molecules (Jackson and Nemerson, 1980; Nemerson 
and Furie, 1980). 
Fig. 7 presents a more detailed structural  representation of 
the active site region in  the derived model of ,&factor XIIa 
and  this same region of trypsin. As is evident from Table  I, 
the amino acid sequence homology between @-factor XIIa  and 
trypsin  in  the active site region is very high, particularly  about 
the catalytic residues His-57 and Ser-195. Thus,  not unex- 
pectedly, the  resultant  tertiary  structure model for ,&factor 
XIIa  in  this region in nearly identical to  that observed for 
trypsin. 
Also drawn solely for illustrative purposes is that portion 
of the bovine pancreatic  trypsin  inhibitor  (Pro-13 to Ala-16) 
bound in the active site of trypsin (Fig.  7B, Marquart et al., 
1983). These inhibitor residues serve to demonstrate how 
substrates  bind  within the active site of trypsin. Although the 
identical  placement of this inhibitor peptide in  the active site 
of @-factor XIIa is arbitrary, it clearly illustrates that  this 
enzyme could bind  peptide  substrates  in a manner similar to 
trypsin and  other serine  proteases  (James et al., 1980). 
The precise physiological substrates cleaved by @-factor 
XIIa have yet to be determined definitively. In general, the 
enzyme shows a trypsin-like cleavage specificity, with a dis- 
tinct preference for argininyl over lysyl peptide bonds (Rad- 
cliffe and Nemerson, 1976; Kurachi and Davie, 1977; Gold- 
smith et al., 1978). One potential factor in this observed 
preference for argininyl peptide bonds was suggested from our 
current model building approach. The positively charged 
amino end of the lysyl side chain in the primary binding 
pocket of trypsin  forms a salt bridge to Asp-189 and hydrogen- 
bonded interactions to Ser-190. The hydroxyl group of Ser- 
190 significantly restricts the positioning of the lysyl side 
chain at the b$ttom  of. the S1 binding subsite (Ser-190 OG- 
Lys NZ 3.13 A). In our putative model of the @-factor  XIIa 
active site, this  interaction is absent since an alanine residue 
is present at position 190 of this enzyme. This amino acid 
substitution could reasonably be expected to produce two 
results (see Fig. 7). First, factor XIIa would have a lower 
affinity for lysyl side chains due to  the absence of a hydrogen- 
bonded interaction to  the hydroxyl of Ser-190. Secondly, the 
increased volume at  the bottom of the primary binding subsite 
could more easily accommodate the larger and more  rigid side 
chain of arginine. It is  worth  noting that  at least four other 
serine  proteases involved in  the blood clotting cascade (throm- 
bin, factor Xa, tPA, and activated protein  C), which have a 
preference for cleavage at arginines (see Jackson  and Nem- 
erson, 1980), also, have the alanine residue at position 190 in 
their  amino acid sequences. Thus,  examination of the @-factor 
XIIa  structural model provides at least a partial explanation 
for argininyl side chain preference for these enzymes. 
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